Investor desk
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Meeting on the.
← Back to Events
Tier 1 Global Networking: High GENERAL CONCLUDED
Meeting on the — 2026 — Rome, Italy
Medical devices, diagnostics, imaging and digital technologies are making a significant impact on the lives of people around the globe. These advances are being made by scientists, entrepreneurs, academics, investors, and an entire community of medtech leaders and innovators. The
3 Presentations
1 Companies
Presentation data updated Jun 15, 2026, 9:50 AM UTC
Why This Event Matters
Medical devices, diagnostics, imaging and digital technologies are making a significant impact on the lives of people around the globe.
Industry impact
Medical devices, diagnostics, imaging and digital technologies are making a significant impact on the lives of people around the globe.
Market implications
Expect signals on pricing, formulary strategy, and partnership economics relevant to general markets in the EU region.
Regulatory implications
EMA and national HTA frameworks are frequently debated at general industry gatherings.
Investor implications
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Meeting on the.
Competitive implications
Competitive positioning among top general players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
32 /100 composite
Meeting on the is a targeted general forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: speaker calibre and KOL density.
- Media coverage 6/20
Niche coverage — subscribe for direct abstract alerts.
- Speaker quality 14/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 0/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 10/20
Some historical catalysts; compare readouts against last cycle.
- Company participation 2/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- Watch plenary: Phase III RASolute 302 topline data
- Watch session: Phase 3 CHALLENGE trial (NCT00819208) results
- Eli Lilly; Boehringer Ingelheim; Sciwind Biosciences carries 1 tracked presentations — map against peer readouts at Meeting on the.
- Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Meeting on the.
- EMA and national HTA frameworks are frequently debated at general industry gatherings.
Timeline & Milestones
- Pre-event intelligence Complete
3 presentations tracked — Key Data and Companies hubs live.
- Conference opens Apr 28, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
Nova editorial monitors confirmed data releases.
- Conference closes Apr 29, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Investors & analysts
Executive Summary
C-level briefMedical devices, diagnostics, imaging and digital technologies are making a significant impact on the lives of people around the globe.
Primary audience: Investors & analysts
Analyst Watch
Regulatory affairs
EMA and national HTA frameworks are frequently debated at general industry gatherings.
Competitive intelligence
Competitive positioning among top general players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
vs. Prior Editions
| Edition | Presentations | Companies |
|---|---|---|
| Meeting on the (current) | 3 | 1 |
| EUROoCS Annual Meeting (2026) | 1 | 0 |
Most Anticipated Presentations
Full data hub → PLENARY
Phase III RASolute 302 topline data
PRESENTATION
Phase 3 CHALLENGE trial (NCT00819208) results
PRESENTATION
Obesity readouts from Eli Lilly, Boehringer Ingelheim, and Sciwind Biosciences
Competitive Landscape
Company map →Competitive positioning among top general players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Related Clinical Trials
1 NCT IDs- NCT00819208 Phase 3 CHALLENGE trial (NCT00819208) results
Coverage & Analysis
No coverage articles yet. Check back closer to the event.
Related News & Research
Research hub →Event Intelligence Summary
Standalone summaries for Meeting on the — optimized for research and AI retrieval.
Executive Summary
Medical devices, diagnostics, imaging and digital technologies are making a significant impact on the lives of people around the globe.
Analyst View
Medical devices, diagnostics, imaging and digital technologies are making a significant impact on the lives of people around the globe.
Investor View
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from Meeting on the.
BD View
BD teams should prioritize networking with presenting companies and services vendors at Meeting on the, focusing on general partnership and licensing opportunities.
Key Facts
- Event
- Meeting on the
- Focus
- general
- Region
- Europe
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is Meeting on the?
Meeting on the is a general industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends Meeting on the?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on general.
Why is Meeting on the important?
Meeting on the influences partnership timing, pipeline prioritization, and policy debates that affect general markets for the next 12–18 months.
When is Meeting on the?
Meeting on the takes place on the scheduled dates.
Where is Meeting on the held?
Meeting on the is held in the listed venue.
What companies participate at Meeting on the?
1+ companies present data or participate in programming at Meeting on the, spanning large pharma, biotech, and services vendors.
What should investors watch at Meeting on the?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on general catalysts during and after Meeting on the.
What BD opportunities exist at Meeting on the?
BD teams use Meeting on the for licensing discussions, co-development talks, and vendor selection across general — especially in networking sessions and satellite meetings.
How does Meeting on the compare with other pharma conferences?
Meeting on the is a tier-1 global congress for general — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of Meeting on the?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for Meeting on the. Subscribe to event alerts on this page for breaking updates.